Journal
JOURNAL OF CONTROLLED RELEASE
Volume 251, Issue -, Pages 92-100Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2017.02.031
Keywords
Oligonucleotides rich in non-methylated CG motifs (CpGs); Virus-like particles (VLPs); Toll-Like Receptor-9 (TLR-9); Plasmacytoid dendritic cells (pDCs); Conventional dendritic cells (cDCs); Cytotoxic T-Lymphocytes (CTLs)
Funding
- Qatar Foundation
- Swiss National Science Foundation [31003A_149925]
- Swiss Cancer League [KFS-2993-08-2012]
- Swiss National Science Foundation (SNF) [31003A_149925] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
DNA rich in unmethylated CGmotifs (CpGs) engage Toll-Like Receptor 9 (TLR-9) in endosomes and are well described stimulators of the innate and adaptive immune system. CpGs therefore can efficiently improve vaccines' immunogenicity. Packaging CpGs into nanoparticles, in particular into virus-like particles (VLPs), improves the pharmacological characteristics of CpGs as the protein shell protects them from DNAse activity and delivers the oligomers to the endosomal compartments of professional antigen presenting cells (APCs). The current consensus in packaging and delivering CpGs in VLP-based vaccines is that both adjuvants and antigens should be kept in close proximity (i.e. physically linked) to ensure delivery of antigens and adjuvants to the same APCs. In the current study, we harness the draining properties of the lymphatic system and show that also non-linked VLPs are efficiently co-delivered to the same APCs in lymph nodes. Specifically, we have shown that CpGs can be packaged in one VLP and mixed with another VLP displaying the antigen prior to administration in vivo. Both VLPs efficiently reached the same draining lymph node where they were taken up and processed by the same APCs, namely dendritic cells and macrophages. This resulted in induction of specific CTLs producing cytokines and killing target cells in vivo at levels seen when using VLPs containing both CpGs and chemically conjugated antigen. Thus, delivery of antigens and adjuvants in separate nanoparticles eliminates the need of physical conjugation and thus can be beneficial when designing precision medicine VLP-based vaccines or help to re-formulate existing VLP vaccines not naturally carrying immunostimulatory sequences. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available